1 |
Li R, Chen W, Lu C, Li X, Chen X, Huang G, Wen Z, Li H, Tao L, Hu Y, Zhao Z, Chen Z, Ni L, Lai Y. A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis. Front Oncol 2022;12:1076303. [PMID: 36727070 DOI: 10.3389/fonc.2022.1076303] [Reference Citation Analysis]
|
2 |
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. Cancer Medicine 2022. [DOI: 10.1002/cam4.5483] [Reference Citation Analysis]
|
3 |
Yu D, Zhang X, Gao L, Qian S, Tang H, Shao N. Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma. Front Oncol 2022;12:924072. [DOI: 10.3389/fonc.2022.924072] [Reference Citation Analysis]
|
4 |
Du W, Guo K, Jin H, Sun L, Ruan S, Song Q. Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis. Front Oncol 2022;12:928619. [DOI: 10.3389/fonc.2022.928619] [Reference Citation Analysis]
|